Best Online Menopause and HRT Providers of 2026
Menopause care has been chronically underserved by mainstream healthcare. Telehealth-first platforms now make bioidentical estradiol, progesterone, vaginal estrogen, and adjuncts like DHEA available at significantly lower price points than legacy clinics. We compared the women's-health-focused providers in our network.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
The Ranking
Broad-catalog telehealth covering hair, skin, weight loss, and sexual health, with free shipping and follow-ups bundled in.
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Doctor-prescribed bioidentical hormone therapy and menopause care for women.
Asynchronous sexual and reproductive healthcare for women across every life stage.
Methodology
Scored on formulary depth (estradiol routes, progesterone, vaginal options), specialist focus, and clinician credentials in menopause medicine.
What the Studies Actually Show
Menopausal hormone therapy (estrogen ± progestogen) is the most effective treatment for vasomotor symptoms. The risk-benefit profile depends on age and time since menopause; the figures below summarise the NAMS 2022 position statement and the Women's Health Initiative long-term follow-up.
| Endpoint | Finding |
|---|---|
| Vasomotor symptom relief (NAMS 2022 position statement)1 | Menopausal hormone therapy (estrogen ± progestogen) is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause |
| Risk-benefit window (timing hypothesis)1 | For symptomatic women under age 60 or within 10 years of menopause onset, benefits typically outweigh risks. Risk profile shifts unfavorably when initiation is delayed beyond age 60 |
| Breast cancer risk (WHI long-term follow-up)2 | Combined estrogen-progestin therapy was associated with a small absolute increase in invasive breast cancer (~8 additional cases per 10,000 person-years); estrogen-alone arm in hysterectomized women showed no increase |
| Bone health2 | Hormone therapy reduces hip and vertebral fractures by ~30–40% in postmenopausal women; effect persists during use |
Frequently Asked Questions
What is BHRT?
Bioidentical Hormone Replacement Therapy uses hormones that are chemically identical to those produced by the body, often compounded to individualized doses.
- NAMS 2022 Position Statement · The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29(7):767–794.
- WHI Long-Term Follow-Up — JAMA 2017 · Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 2017;318(10):927–938.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Which provider is right for you?
Symptom mix and prior HRT experience determine the best clinic match.